Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) (NCT03974022)
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation
🩺 Plain-English Summary (8th-Grade Level)
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Who can join: Review the eligibility criteria below.
Location: University of California, San Diego (UCSD) - Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (124 Sites)
Showing the first 25 of 124 sites.
- University of California, San Diego (UCSD) - Moores Cancer Center — La Jolla, California
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center — Orange, California
- Innovative Clinical Research Institute, LLC — Whittier, California
- University of Colorado Hospital - Anschutz Cancer Pavilion — Aurora, Colorado
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Michigan Center of Medical Research — Farmington Hills, Michigan
- Northwell Health - Centers for Advanced Medicine — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Virginia Cancer Specialists — Fairfax, Virginia
- Fundacion Respirar - Consultorios Medicos Dr. Doreski — Cabildo,
- CEMIC Centro de Educación Médica e Investigaciones Clínicas - Hospital Universitario sede Saavedra — Ciudad Autónoma Buenos Aires,
- Centro Medico Austral OMI — Ciudad Autónoma Buenos Aires,
- Diabaid — Ciudad Autónoma Buenos Aires,
- Fundacion CENIT Para La Investigacion en Neurociencias — Ciudad Autónoma Buenos Aires,
- Instituto Argentino de Diagnositco y Tratamiento S.A. — Ciudad Autónoma Buenos Aires,
- Instituto Medico de la Fundacion de Estudios Clínicos — Ciudad Autónoma Buenos Aires,
- Centro de Investigación Pergamino SA — Pergamino,
- Clinica Viedma S.A — Viedma,
- Blacktown Hospital — Blacktown,
- Chris O'Brien Lifehouse — Camperdown,
- Austin Hospital — Heidelberg,
- St George Hospital — Kogarah,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona
Explore by condition: All Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.